The Buy rating from EF Hutton analyst Michael King indicates a positive outlook for Werewolf Therapeutics. This rating, along with the maintained price target of $8.3, suggests that the stock is expected to perform well in the short term. The news is directly related to the company and is important for investors, as analyst ratings can influence market sentiment and stock prices.